ATE475713T1 - Trans-lentivirales vektor system - Google Patents

Trans-lentivirales vektor system

Info

Publication number
ATE475713T1
ATE475713T1 AT00984421T AT00984421T ATE475713T1 AT E475713 T1 ATE475713 T1 AT E475713T1 AT 00984421 T AT00984421 T AT 00984421T AT 00984421 T AT00984421 T AT 00984421T AT E475713 T1 ATE475713 T1 AT E475713T1
Authority
AT
Austria
Prior art keywords
present
dna encoding
trans
protein
lentiviral
Prior art date
Application number
AT00984421T
Other languages
English (en)
Inventor
John Kappes
Xiaoyun Wu
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Application granted granted Critical
Publication of ATE475713T1 publication Critical patent/ATE475713T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of Vehicle Engines Or Engines For Specific Uses (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00984421T 1999-12-14 2000-12-14 Trans-lentivirales vektor system ATE475713T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/460,548 US6555342B1 (en) 1998-06-03 1999-12-14 Fusion protein delivery system and uses thereof
PCT/US2000/034021 WO2001044481A1 (en) 1999-12-14 2000-12-14 Fusion protein delivery system and uses thereof

Publications (1)

Publication Number Publication Date
ATE475713T1 true ATE475713T1 (de) 2010-08-15

Family

ID=23829157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984421T ATE475713T1 (de) 1999-12-14 2000-12-14 Trans-lentivirales vektor system

Country Status (9)

Country Link
US (4) US6555342B1 (de)
EP (1) EP1244797B1 (de)
JP (1) JP4842482B2 (de)
AT (1) ATE475713T1 (de)
AU (1) AU785283B2 (de)
CA (1) CA2394261C (de)
DE (1) DE60044754D1 (de)
NZ (1) NZ519671A (de)
WO (1) WO2001044481A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449858T1 (de) * 1999-10-11 2009-12-15 Pasteur Institut Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
GB0024550D0 (de) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20040091853A1 (en) * 2001-03-02 2004-05-13 Hazuda Daria J. Viral reporter particles
EP1412493B1 (de) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor-produktionssystemen
EP1438075A4 (de) 2001-10-02 2006-04-19 Inst Clayton De La Rech Verfahren und zusammensetzungen in verbindung mit lentiviralen vektoren mit begrenzter expression und ihre anwendungen
WO2003059923A2 (en) * 2001-12-21 2003-07-24 Tranzyme, Inc. Methods and compositions for generating a genetically modified animal using lentiviral vectors
US20050214945A1 (en) * 2002-05-17 2005-09-29 Eastern Virginia Medical School Htlv-I tax induced killing of p53 null cancer cells
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP3663395B1 (de) 2012-03-26 2024-07-31 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology, Transfer, Verabreichung von verkapselter rna an säugerzellen
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
AU2014365777B2 (en) 2013-12-16 2020-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
US10940200B2 (en) 2015-09-28 2021-03-09 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
WO2022032228A1 (en) 2020-08-07 2022-02-10 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2025137290A1 (en) 2023-12-19 2025-06-26 The Broad Institute, Inc. Methods and systems directed to therapeutic delivery of the human gba1 gene

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE275259C (de)
GB8818020D0 (en) 1988-07-28 1988-09-01 Ici Plc Method for amplification of nucleotide sequences
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5175099A (en) 1989-05-17 1992-12-29 Research Corporation Technologies, Inc. Retrovirus-mediated secretion of recombinant products
ATE127520T1 (de) 1989-06-02 1995-09-15 Dana Farber Cancer Inst Inc Protein mit transaktivierender eigenschaft, dieses protein exprimierende vektoren, zellinien und seine verwendungen.
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ATE147782T1 (de) 1990-07-12 1997-02-15 Harvard College Primaten-lentivirus impfstoffe
JPH08500965A (ja) 1992-05-22 1996-02-06 デイナ ファーバー キャンサー インスチチュート ハイブリッドウイルス発現ベクター，その使用および新規アッセイ
WO1993025235A1 (en) 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides
WO1994017825A1 (en) 1993-02-05 1994-08-18 The Regents Of The University Of California Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
WO1995016705A1 (en) 1993-12-15 1995-06-22 The Trustees Of The University Of Pennsylvania Vpr receptor protein
CA2186398A1 (en) 1994-03-25 1995-10-05 Ahmed A. Azad Vpr and vpx proteins of hiv
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5639619A (en) 1994-10-13 1997-06-17 Regents Of The University Of California Screening assay for anti-HIV drugs using the Vpr gene
DE69637677D1 (de) * 1995-04-14 2008-10-23 Univ Alabama Res Found Transfer system basierend auf einem fusionsprotein und seine anwendungen.
US6200811B1 (en) 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
PT1076715E (pt) 1998-05-13 2007-10-26 Genetix Pharmaceuticals Inc Células empacotadoras lentivirais
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
EP1244797A1 (de) 2002-10-02
US20050014260A1 (en) 2005-01-20
AU785283B2 (en) 2006-12-21
EP1244797A4 (de) 2004-07-28
CA2394261C (en) 2012-09-04
AU2104301A (en) 2001-06-25
US7259014B2 (en) 2007-08-21
CA2394261A1 (en) 2001-06-21
NZ519671A (en) 2004-10-29
JP4842482B2 (ja) 2011-12-21
DE60044754D1 (de) 2010-09-09
EP1244797B1 (de) 2010-07-28
JP2003519476A (ja) 2003-06-24
WO2001044481A1 (en) 2001-06-21
US6555342B1 (en) 2003-04-29
US20080233639A1 (en) 2008-09-25
US20110229964A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
DE60044754D1 (de) Trans-lentivirales Vektor System
DE69637677D1 (de) Transfer system basierend auf einem fusionsprotein und seine anwendungen.
Ropers et al. Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA
Grassmann et al. In vitro binding of human T-cell leukemia virus rex proteins to the rex-response element of viral transcripts
DE69830663D1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
DK1224314T3 (da) Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
ATE514783T1 (de) Plasmidsystem zur expression mehrerer gene
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
Ricci et al. Lentiviral RNAs can use different mechanisms for translation initiation
YU150891A (sh) Rekombinantna genetska informacija
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
LaPierre et al. Sequence and transcriptional analyses of the fish retroviruses walleye epidermal hyperplasia virus types 1 and 2: evidence for a gene duplication
ATE280947T1 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
Nappi et al. Identification of a novel posttranscriptional regulatory element by using a rev-and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap
DK1082423T3 (da) Cyclin E2-gener og -proteiner
MXPA94001321A (es) Funcion y actividad de la proteina viral r.
Hofacre et al. Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
Heger et al. Multimer formation is not essential for nuclear export of human T-cell leukemia virus type 1 Rex trans-activator protein
Potash et al. Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif
PT871757E (pt) Vectores virais condicionalmente replicantes e sua utilizacao
EP1412374A4 (de) Neue pgc-1-isoformen und deren verwendungen
Taylor et al. A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat
Patrick et al. Insights into the protein domains of C-VI TRIM subfamily in viral infection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties